Answers are grounded in this paper and cite their sources.
Umbilical cord mesenchymal stem cells (UCMSCs) can effectively restore the fertility of female animals suffering from premature ovarian failure (POF). However, UCMSCs were senescent gradually during continuous expansion in vitro which limited their clinical applications. Currently, there is still lack of a safety and efficiency method to delay the senescence of UCMSCs. Therefore, the aim of this study was to access whether Vitamin C (Vc) can rejuvenate senescent UCMSCs, with a specific focus on their therapeutic effect in a murine model of premature ovarian failure. The cellular and molecular characteristics of UCMSCs at early passage (passage 6, P6), high passage (passage 12, P12) with or without Vc treatment were analyzed using flow cytometry, transmission electron microscope, bulk RNA sequencing and western blotting, etc. The murine model of POF was established via intraperitoneal injection of busulfan and Cyclophosphamide, then UCMSCs at P12 with or without Vc-treated were respectively transplanted into the POF mice to evaluate the therapeutic effect, meanwhile POF mice injected with UCMSCs at P6 and normal mice were used as positive controls, POF mice injected with equal volume of PBS were used as a negative control. The mice in treatment group were treated with UCMSCs every week for 3 consecutive times. ELISA, HE staining were applied to evaluate the ovarian function, and fertility was performed by mating. We found UCMSCs exhibited senescent phenotype and loss of stemness, especially in decreasing of mitochondrial function and autophagy level after expansion for 12 times. Moreover, we demonstrated that treated cells with 30 µg/mL Vitamin C for 48 h could rejuvenate UCMSCs at passage 12 (P12) by significantly improving mitochondrial function and restoring autophagy ( P < 0.05). UCMSCs transplantation, both UCMSCs at the early passage and those at high passage, significantly improved the ovarian function and fertility of POF mice ( P < 0.05). Notably, these therapeutic effects (including restoring estrous cycle, hormone secretion ability, follicular reserve, litter size, etc.) were more significant in Vc-treated P12 UCMSCs group than in P12 UCMSCs without Vc pretreatment ( P < 0.05), which were equaled to those of UCMSCs at P6. In summary, these findings demonstrate that Vc could effectively rejuvenate and maintain therapeutic potential of UCMSCs at high passage, providing a feasible strategy of improving the efficiency of UCMSCs utilization as well as facilitating clinical application in future.
No takes yet. Share an insight, caveat, or question.
She et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: